The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Yutaka Fujiwara
No relevant relationships to disclose
Naomi Kiyota
No relevant relationships to disclose
Masanori Toyoda
No relevant relationships to disclose
Takanobu Shimada
No relevant relationships to disclose
Yoshinori Imamura
No relevant relationships to disclose
Toru Mukohara
No relevant relationships to disclose
Hironobu Minami
No relevant relationships to disclose